CLINICAL_TRIALS
trial_result
· 2018-03-09
Clinical Trial Update: Versartis Long-Term Safety Study of Somavaratan [Phase 2, Phase 3]
Summary
A long-term safety study of somavaratan (VRS-317) for pediatric growth hormone deficiency in Phase 2/Phase 3 has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Versartis Inc. | Conditions: Pediatric Growth Hormone Deficiency | Phase 2, Phase 3 | Status: TERMINATED